|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | 胰腺的癌症病人的反应评估追随者 neoadjuvant 治疗显示文摘 Pancreatic ductal adenocarcinoma(PDAC) is one of the most aggressive human neoplastic entities,with a very poor prognosis characterized by a high mortality rate and short survival.This is due both to its aggressive biological behaviour and the high incidence of locally advanced stages at the time of the initial diagnosis.The limits of resectability and the role of neoadjuvant(radio) chemotherapy for PDAC management are still unclear.A recently published article by Kats et al compared the radiological,surgical and histopathological results of 129 patients with borderline resectable tumors undergoing neoadjuvant treatment followed by surgery.Although post-neoadjuvant treatment imaging implied a low response rate,a high rate of complete resections was achieved.This seems to confirm that,though radiology has made a significant progress in defining locally advanced PDAC,there is place for further improvement.In particular,the differentiation between radiotherapy-induced scarring/fibrosis and cancer-associated desmoplasia remains a clinical/radiological challenge.Though selection of patients with occult systemic disease is possible with neoadjuvant treatment,downstaging does not seem to occur frequently.Thus,development of novel,more aggressive(radio) chemotherapy regimens is required to improve prognosis of patients with locally unresectable but not systemically micro-metastasized tumors. | Chiara Tosolini Christoph W Michalski Jrg Kleeff | 2013 | World Journal of Gastrointestinal Surgery2013，5，2： | 7 |
| 2 | Update on surgical treatment of pancreatic neuroendocrine neoplasms显示文摘Pancreatic neuroendocrine neoplasms(PNENs) are rare and account for only 2%-4% of all pancreatic neoplasms. All PNENs are potential(neurendocrine tumors PNETs) or overt(neuroendocrine carcinomas PNECs) malignant,but a subset of PNETs is low-risk. Even in case of low-risk PNETs surgical resection is frequently required to treat hormone-related symptoms and to obtain an appropriate pathological diagnosis. Low-risk PNETs in the body and the tail are ideal for minimallyinvasive approaches which should be tailored to the individual patient. Generally,surgeons must aim for parenchyma sparing in these cases. In high-risk and malignant PNENs,indications for tumor resection are much wider than for pancreatic adenocarcinoma,in many cases due to the relatively benign tumor biology. Thus,patients with locally advanced and metastatic PNETs may benefit from extensive resection. In experienced hands,even multi-organ resections are accomplished with acceptable perioperative morbidity and mortality rates and are associated with excellent long term survival. However,poorly differentiated neoplasms with high proliferation rates are associated with a dismal prognosis and may frequently only be treated with chemotherapy. The evidence on surgical treatment of PNENs stems from reviews of mostly singlecenter series and some analyses of nation-wide tumor registries. No randomized trial has been performed to compare surgical and non-surgical therapies in potentially resectable PNEN. Though such a trial would principally be desirable,ethical considerations and the heterogeneity of PNENs preclude realization of such a study. In the current review,we summarize recent advances in the surgical treatment of PNENs. | Jan G D’Haese Chiara Tosolini Güralp O Ceyhan Bo Kong Irene Esposito Christoph W Michalski J?rg Kleeff | 2014 | World Journal of Gastroenterology2014，20，38： | 4 |
| 3 | Viral-mediated gene therapy for spinal cord injury(SCI) from a translational neuroanatomical perspective显示文摘Repairing spinal cord injury(SCI)is one of the most challenging endeavours currently faced by neuroscientists.One promising therapeutic avenue to reverse this once considered permanent condition is gene therapy,however progress has been hampered by the anatomica intricacy of the spinal cord itself as well as by the sheer complexity of the molecular cascades of events that take place in the injured cord. | Andrew P Tosolini Renée Morris | 2016 | Neural Regeneration Research2016，11，5： | 2 |
| 4 | Clinical impact of different classes of infiltrating T cytotoxic and helper cells ( Thl, th2, treg, thl7 ) in patients with colorectal cancer 显示文摘 | Tosolini M Kirilovsky A Mlecnik B | 2011 | Cancer Res2011，71，4： | 1 |
| 5 | Clinical impact of different classes of infiltrating T cytotoxic and helper cells ( Thl, th2, treg, th17) in patients with colorectal cancer显示文摘 | Tosolini M Kirilovsky A Mlecnik B | 2011 | Cancer Res2011，71，4： | 1 |
| 6 | Clinical impact of different classes of infiltrating T cytotoxic and helper cells(Th1,th2,treg,th17)in patients with colorectal cancer显示文摘 | Tosolini M Kirilovsky A Mlecnik B | 2011 | Cancer Res2011，71，4： | 1 |
| 7 | Clinical impact of different classes of infiltrating T cytotoxic and helper cells(Th1, Th2, Treg, Th17) in patients with colorectal cancer显示文摘 | Tosolini M Kirilovsky A Mlecnik B | 2011 | Cancer Res2011，71，4： | 1 |
| 8 | Clinical impact of differ- ent elasses of infiltrating T eytotoxie and helper cells ( Thl, th2, treg,thl7 )in patients with coloreetal cancer 显示文摘 | Tosolini M Kirilovsky A Mlecnik B | 2011 | 'Cancer Res2011，71，4： | 1 |
| 9 | Biomolecular network reconstruction identifies T-cell homing factors associated with surviv- al in colorectal cancer 显示文摘 | Mlecnik B Tosolini M Charoentong P | 2010 | Gastroenterology2010，138，4： | 1 |
| 10 | Clinical im- pact of different classes of in fhrating T cytotoxic and helper ceils (Thl, th2, treg, th17)in patients with colorectal cancer 显示文摘 | TOSOLINI M KIRILOVSKY A MIECNIK B | 2011 | Cancer Res2011，71，4： | 1 |
| 11 | The OSCE method (Objective Structured Clinical Examination) in the university course for nurses in Udine显示文摘 | Bulfone G Zanini A Tosolini C | 2006 | Assist Inferm Rio2006，25，3： | 1 |
| 12 | Clinical impact of different classes of infiltrating T cytotoxic and helper cells ( Thl, th2, treg, th17 ) in patients with colorectal cancer显示文摘 | Tosolini M Kirilovsky A Mlecnik B | 2011 | Cancer Res2011，71，4： | 1 |
| 13 | Clinical impact of different classes of infiltrating T cytotoxic and helper cells ( Thl, Th2, Treg, Thl7) in patient with colorectal cancer显示文摘 | Tosolini M Kirilovsky A Mlecnik B | 2011 | Cancer Res2011，71，4： | 1 |
| 14 | Clinical impact of different classes of infiltrating T eytotoxic and helper cells (Thl, Th2, Treg, Thl7 ) in patients with colorectal cancer 显示文摘 | Tosolini M Kirilovsky A Mlecnik B | 2011 | Cancer Res2011，71，： | 1 |
| 15 | Mapping of AKT3,encoding a member of the AKT/protein kinase B family,to human and rodent chromosomes by fluorescence in situ hybridization显示文摘 | Murthy SS Tosolini A Taguchi T | 2000 | Cytogenet Cell Genet2000，88，12： | 1 |
| 16 | Histopathologic-based prognostic factors of colorectal cancers are associated with the state of the local immune reaction显示文摘 | Mlecnik B Tosolini M Kirilovsky A | 2011 | J Clin Oncol2011，29，6： | 1 |
| 17 | Coordination of in-tratumoral immune reaction and human colorectal cancer recurrence显示文摘 | Camus M Tosolini M Mlecnik B | 2009 | Cancer Res2009，69，6： | 1 |
| 18 | Clinical impact of different classes of infiltrating T cytotoxic and helper cells(Th1,th2,treg,th17)in patients with colorectal cancer显示文摘 | Tosolini M Kirilovsky A Mlecnik B | 2011 | Cancer Res2011，71，4： | 1 |
| 19 | Clinical impact of different classes of infiltrating T cytotoxic and helper cells (Thl, th2, treg, th17) in patients with colorectal cancer 显示文摘 | Tosolini M Kirilovsky A Mlecnik B | 2011 | Cancer Res2011，71，4： | 1 |
| 20 | Spatiotemporal Dynamics of Intratumoral Immune Cells Reveal the Immune Landscape in Human Cancer显示文摘 | Gabriela Bindea Bernhard Mlecnik Marie Tosolini Amos Kirilovsky Maximilian Waldner Anna C. Obenauf Helen Angell Tessa Fredriksen Lucie Lafontaine Anne Berger Patrick Bruneval Wolf Herman Fridman Christoph Becker Franck Pagès Michael R. Speicher Zlatko Tra | 2013 | Immunity2013，，4： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员